Seaport Therapeutics (NASDAQ:SPTX) Shares Break Above Fifty Day Moving Average – Should You Sell?

Seaport Therapeutics, Inc. (NASDAQ:SPTX)’s share price passed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $20.68 and traded as high as $21.75. Seaport Therapeutics shares last traded at $21.50, with a volume of 227,030 shares changing hands.

More Seaport Therapeutics News

Here are the key news stories impacting Seaport Therapeutics this week:

• Positive Sentiment: Director Denice Torres bought 5,000 shares for about $99,300 at an average price of $19.86, a notable insider purchase that may signal confidence in the company. Article: Seaport Therapeutics Director Purchases Shares
• Positive Sentiment: JPMorgan raised its price target to $41 from $40 and maintained an Overweight rating. HC Wainwright also reiterated its Buy rating and $50 target, reflecting continued analyst optimism, though targets are not guarantees. Seaport Therapeutics analyst information
• Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it narrowed its projected FY2026 loss to $3.95 per share from $4.09 and improved its Q4 2026 and Q1 2027 estimates, but its Q3 and Q4 2027 estimates imply somewhat larger losses. The revisions are modest and do not change its Buy rating or $50 target.
• Positive Sentiment: Seaport’s latest reported quarterly loss of $0.49 per share was better than the $0.58 loss analysts expected, providing a recent earnings beat that may help cushion concerns about future losses.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SPTX. Weiss Ratings raised Seaport Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday. JPMorgan Chase & Co. upped their target price on Seaport Therapeutics from $40.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday. JonesTrading initiated coverage on shares of Seaport Therapeutics in a report on Wednesday, August 26th. They set a “buy” rating and a $32.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Seaport Therapeutics in a research report on Thursday, October 8th. Finally, Seaport Research Partners set a $28.00 target price on shares of Seaport Therapeutics in a report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.12.

Seaport Therapeutics Price Performance

The stock’s fifty day simple moving average is $20.68. The firm has a market cap of $1.15 billion and a P/E ratio of -1.77.

Seaport Therapeutics (NASDAQ:SPTX) last issued its earnings results on Monday, November 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.09. Equities research analysts forecast that Seaport Therapeutics, Inc. will post -4.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Denice Torres acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The shares were purchased at an average price of $19.86 per share, with a total value of $99,300.00. Following the transaction, the director directly owned 5,000 shares in the company, valued at approximately $99,300. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional Investors Weigh In On Seaport Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. TRV GP VI LLC bought a new position in shares of Seaport Therapeutics in the second quarter valued at $44,769,742. Citadel Advisors LLC acquired a new stake in shares of Seaport Therapeutics in the 2nd quarter worth about $4,152,000. The Manufacturers Life Insurance Company bought a new stake in shares of Seaport Therapeutics during the 2nd quarter valued at $1,793,000. State Street Corp bought a new stake in shares of Seaport Therapeutics in the second quarter worth about $1,448,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Seaport Therapeutics in the 2nd quarter worth $1,629,000.

Seaport Therapeutics Company Profile

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company uses its Glyph platform, a technology designed to create prodrugs that may improve the delivery, tolerability, and effectiveness of certain therapies, including treatments intended to reach the brain.

Seaport’s pipeline includes investigational therapies for neurological and neuropsychiatric conditions. Its programs have included GTX-102, an oral investigational medicine being developed for Angelman syndrome, a rare genetic neurodevelopmental disorder, as well as additional candidates aimed at addressing unmet needs in CNS care.

The company was established with support from PureTech Health and is headquartered in Boston, Massachusetts.